Leslie Williams, hC Bioscience CEO

Ex­clu­sive: Mt. Ever­est al­most got in the way of a tR­NA biotech, but hC Bio­science climbs to Se­ries A ex­ten­sion

A Take­da and ARCH-backed start­up look­ing to prove out the next po­ten­tial RNA gold­mine in drug R&D has se­cured more cap­i­tal en route to a 2024 clin­i­cal en­try, CEO Leslie Williams tells End­points News.

The biotech, hC Bio­science, al­most nev­er came to be. Williams was set to climb Mount Ever­est in 2020. But the Covid-19 pan­dem­ic had oth­er plans, so the vet­er­an biotech CEO had time to go full throt­tle on en­gag­ing the lab at the Uni­ver­si­ty of Iowa that pro­duced a 2019 pa­per in Na­ture Com­mu­ni­ca­tions and then se­cure the IP, gath­er feed­back from sci­en­tists and then form a sto­ry to tell in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.